The company intends to carry out the inquiry work for this non-public offering of shares. The company's shares will be suspended from the opening of the market on October 21. It is expected that the suspension will not exceed 5 trading days. Trading will resume on the next trading day after the end of the subscription target quotation.

West Pump shares: the controlling shareholder and the actual controller intend to increase the shares of the company.

Wanxi Holdings, the controlling shareholder of West Pump Co., Ltd. (002536), plans to increase its holdings of the company's total share capital within six months from October 21, 2016 through the methods permitted by the Shenzhen Stock Exchange trading system (including but not limited to centralized bidding and block transactions). 0.5-1.5 shares; Sun Yaozhong, the actual controller, plans to increase the company's total share capital within six months from October 21, 2016, increase its shareholding by 0.05-0.2 of the Company's total share capital by means permitted by the trading system of the Shenzhen Stock Exchange (including but not limited to centralized bidding and block trading).

Tonghua Jinma (15.050, -0.15, -0.99): New Alzheimer's Drug Enters Phase III Clinical Trial

Changchun Huayang High-tech Co., Ltd., a subsidiary of Tonghua Jinma (000766), and Jiangsu Sheneryang High-tech Co., Ltd. jointly developed and developed a new class of 1.1 drugs for the treatment of Alzheimer's disease, amber octahydrotriacridine tablets, which has been obtained in August 2015. Phase III drug clinical trial approval issued by the State Food and Drug Administration. At present, Huayang and Sheneryang have signed the "Clinical Trial (Entrustment) Contract" with Beijing Bonacia Pharmaceutical Technology Co., Ltd. on the Phase III clinical trial of Amber Eight Hydrohydrotriacridine Tablets, determined the Phase III clinical trial plan, completed the production of the test and reference products, and obtained the ethical approval issued by the Ethics Committee. According to the relevant regulations, amber eight hydrogen triacridine tablets can be officially entered into phase III clinical trials. There is a certain degree of uncertainty as to whether the phase III clinical trial of amber eight hydrotriacridine tablets is successful and whether it will be approved by the State Food and Drug Administration in the future.

Guangyunda: Restructuring application accepted by SFC

Guangyunda (300227) received the China Securities Regulatory Commission's "China Securities Regulatory Commission Administrative License Application Acceptance Notice" on October 21, 2016, and accepted the materials submitted by the company. The Company's issuance of shares and payment of cash for the purchase of assets and raising of matching funds are subject to the approval of the CSRC.

Chengfei Integration (27.150, -0.49, -1.77) Corrects Expected Change in Net Profit for 2016

The company announced that the change in net profit attributable to shareholders of listed companies in 2016 was corrected from 120.00 to 170.00 percent to 20.00 to 70.00 percent.